<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations of cisplatin for 72 h. Proliferation was measured using the MTT assay. While cisplatin inhibited the growth of both PT and CisR cell lines, the inhibitory effect of cisplatin was greatly reduced in CisR cells relative to parent cells. Data are expressed as Mean ± SEM from three independent experiments (n = 3) (*p<0.001 vs PT untreated, <sup>$$</sup>p<0.001 vs CisR untreated, <sup>#</sup>p<0.001 PT vs CisR,<sup> $</sup>p<0.01 vs CisR untreated [A549], <sup>$</sup>p<0.01 PT vs CisR, <sup>#$</sup>p<0.05 PT vs CisR [MOR]).</p
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
INTRODUCTION: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...
<p>Parent and resistant cell lines were treated with cisplatin for 72 h. Apoptotic cells, as measure...
<p>(A) NSCLC cells were treated with increasing concentrations of cisplatin (0.1 µM–100 µM) for 72 h...
<p>(A) Representative phase contrast microscopy images of THJ-11T parental monolayer-derived cells e...
<p>A549, SKMES-1, MOR and H460 PT and CisR cells were seeded in 6-well plates using optimised seedin...
<p>(<b>A</b>) CNE2 and HONE1 stable cell lines were treated with 0 or 2.0 μg/ml cisplatin. The MTT a...
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resist...
<p>Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...
<p>SKOV3 (A, C) and SKOV3/DDP (B, D) cell viability was inhibited in a dose-dependent manner by trea...
Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell de...
<p>Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
INTRODUCTION: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...
<p>Parent and resistant cell lines were treated with cisplatin for 72 h. Apoptotic cells, as measure...
<p>(A) NSCLC cells were treated with increasing concentrations of cisplatin (0.1 µM–100 µM) for 72 h...
<p>(A) Representative phase contrast microscopy images of THJ-11T parental monolayer-derived cells e...
<p>A549, SKMES-1, MOR and H460 PT and CisR cells were seeded in 6-well plates using optimised seedin...
<p>(<b>A</b>) CNE2 and HONE1 stable cell lines were treated with 0 or 2.0 μg/ml cisplatin. The MTT a...
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resist...
<p>Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...
<p>SKOV3 (A, C) and SKOV3/DDP (B, D) cell viability was inhibited in a dose-dependent manner by trea...
Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell de...
<p>Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...
Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management...
INTRODUCTION: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in ...